Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With IIIB-IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health - Care System in China.

Zhu, Chen; Xing, Xiao-Xuan; Wu, Bin; Liang, Gang; Han, Gang; Lin, Cai-Xia; Fang, Hong-Mei

Zhu, Chen; Xing, Xiao-Xuan; Wu, Bin; Liang, Gang; Han, Gang; Lin, Cai-Xia; Fang, Hong-Mei.

Afiliação

Zhu C; Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Xing XX; Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing, China.
Wu B; Medical Decision and Economic Group, Department of Pharmacy, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Liang G; Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Han G; Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Lin CX; Department of Pharmacy, The People's Hospital of Jiangshan, Jiangshan, China.
Fang HM; Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

Front Pharmacol ; 12: 735536, 2021.

Article em En | MEDLINE | ID: mdl-35002693

Palavras-chave

CAMEL; NSCLC; camrelizumab; cost-effectiveness; nonsquamous non-small cell lung cancer

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Clinical_trials / Health_economic_evaluation / Prognostic_studies Idioma: En Revista: Front Pharmacol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google